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Abstract: Anaplastic lymphoma kinase (ALK) translocation is an actionable mutation in lung
adenocarcinoma. Nonetheless tumour consists of heterogeneous cell subpopulations with diverse
phenotypes and genotypes, and cancer cells can actively release extracellular vesicles (EVs) to
modulate the phenotype of other cells in the tumour microenvironment. We hypothesized that EVs
derived from a drug-resistant subpopulation of cells could induce drug resistance in recipient cells.
We have established ALK-translocated lung adenocarcinoma cell lines and subclones. The subclones
have been characterized and the expression of EV-RNAs determined by quantitative polymerase
chain reaction. The effects of EV transfer on drug resistance were examined in vitro. Serum EV-RNA
was assayed serially in two patients prescribed ALK-tyrosine kinase inhibitor (ALK-TKI) treatment.
We demonstrated that the EVs from an ALK-TKI-resistant subclone could induce drug resistance in
the originally sensitive subclone. EV-RNA profiling revealed that miRNAs miR-21-5p and miR-486-3p,
and lncRNAs MEG3 and XIST were differentially expressed in the EVs secreted by the resistant
subclones. These circulating EV-RNA levels have been found to correlate with disease progression
of EML4-ALK-translocated lung adenocarcinoma in patients prescribed ALK-TKI treatment. The
results from this study suggest that EVs released by a drug-resistant subpopulation can induce drug
resistance in other subpopulations and may sustain intratumoural heterogeneity.
Keywords: extracellular vesicles; TKI-resistance; anaplastic lymphoma kinase; non-small cell lung
cancer; intratumoural heterogeneity

1. Introduction
Rearrangement of chromosome 2 leads to fusion of the echinoderm microtubule-associated
protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) gene to form the constitutively active
EML4-ALK oncoprotein. Although EML4-ALK fusion occurs in only 3–5% of lung adenocarcinomas [1],
it is a therapeutic target in non-small cell lung cancer (NSCLC).
The first-generation ALK-tyrosine kinase inhibitor (TKI) crizotinib is a small molecule TKI of
ALK, MET and ROS1 kinases. Crizotinib was previously the recommended first-line treatment
for ALK-translocated NSCLC. Although most cases of ALK-translocated NSCLC respond initially
to crizotinib, disease progression occurs approximately one year after treatment. The resistance
Cancers 2019, 11, 104; doi:10.3390/cancers11010104
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mechanisms of crizotinib can be classified as acquisition of secondary mutations in the ALK kinase
domain, ALK fusion gene amplification, or activation of bypass signaling pathways [2]. Ceritinib
and alectinib are second-generation ALK inhibitors with improved potency and selectivity against
the kinase activities of ALK. Due to its proven superior efficacy and lower toxicity, Alectinib is now
approved as first-line treatment for ALK NSCLC and in patients prescribed crizotinib in whom disease
progression has occurred.
Intratumoural heterogeneity (ITH) has been recognized in all types of cancer. The subpopulations
of tumour cells with diverse phenotypes and genotypes contribute to treatment resistance and
metastasis in lung cancer [3]. Dynamic interactions between subpopulations of tumour cells
and stromal cells within the tumour microenvironment are believed to be critical for tumour
maintenance, and may also drive the development of drug resistance. Blocking of relevant inter-cellular
communications may create a therapeutic window for overcoming drug resistance [4].
Extracellular vesicles (EVs) include exosomes, microvesicles, and apoptotic bodies. Exosomes, in
particular those with 30–150 nm diameter, are secreted by most cell types into bodily fluids including
blood, urine and cerebrospinal fluid, as well as in supernatants from cultured cells [5]. Tumour-derived
EVs that contain biomolecules (i.e., proteins, DNA and RNA) can mediate communications between
different subpopulations of cells within a tumour or between cells at distant metastatic sites. These
paracrine and endocrine functions of EVs have been implicated in modulation of the tumour
microenvironment [6] and creation of pre-metastatic niches at distant sites [7,8]. EVs are comprised
of a phospholipid bilayer that preserves and stabilizes different types of RNA (e.g., messenger RNA
[mRNA], long non-coding RNA [lncRNA] and microRNA [miRNA]) [9,10]. Analysis of cancer-derived
EV-associated RNA contents can enable decryption of the biological messages released from cancer cells.
Recent studies have demonstrated that cancer-derived EV-RNAs can also serve as novel circulating
diagnostic or prognostic biomarkers for lung cancers [11]. Furthermore, engineered EVs that contain
short interfering RNA have been shown to facilitate oncogene-targeted therapy in cancer [12].
The aims of this study were: (1) To establish subclones of ALK-translocated NSCLC cell lines with
known drug sensitivity and resistance to crizotinib or ceritinib; (2) To identify the EV-associated RNAs
involved in transmission of drug resistance and migration capability from ALK-TKI-resistant subclones
to drug-sensitive subclones; (3) To determine whether these EV-associated RNAs involved in drug
resistance correlate with treatment response in patients with ALK–translocated lung adenocarcinoma.
2. Results
2.1. Characterization of EML4-ALK Lung Adenocarcinoma Cell Line Subclones
Subclones (Figure 1A,B) were established respectively by single cell cloning or cloning cylinders
from each of the parental lung adenocarcinoma cell lines, FA34 and FA121. ALK break apart FISH
assays were used to confirm ALK chromosome rearrangement in all parental and subclone cell lines.
Consistent chromosome rearrangements were detected in all FA34 (Figure 1C) and FA121 (Figure 1D)
cell lines and their respective subclones. PCR products with size 1055 bp were obtained from all the
cell lines and subclones (Figure 1E); this confirmed that all has variant 2 of EML4-ALK rearrangement
(i.e., fusion at exon 20 of EML4 with exon 20 of ALK). The sensitivity of these cell lines against the
three ALK-tyrosine kinase inhibitors (TKI), namely crizotinib, ceritinib and alectinib, was examined
(Table 1). The potency of the two second-generation ALK-TKIs, ceritinib and alectinib, was higher than
that of the first-generation ALK-TKI crizotinib in all the subclones. Different subclones derived from
the same cell line showed variations in sensitivity to the same ALK-TKIs (Table 1A).
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(E) EML4-ALK variant 2 was reconfirmed by reverse transcription-polymerase chain
reaction (RT-PCR) in all FA34 and FA121 parental lines and their subclones. Generation of crizotinibreaction (RT-PCR) in all FA34 and FA121 parental lines and their subclones. Generation of crizotinibor ceritinib-resistant EML4-ALK lung adenocarcinoma cell lines (F) FA34 and (G) FA121. Crizotinibor ceritinib-resistant EML4-ALK lung adenocarcinoma cell lines (F) FA34 and (G) FA121. Crizotinib(Cr) or ceritinib (Ce)-resistant subclones derived from prolonged stepwise (S) or high concentration
(Cr) or
ceritinib (Ce)-resistant subclones derived from prolonged stepwise (S) or high concentration (H)
(H) treatment on (A) FA34 subclones or (B) FA121 subclones.
treatment on (A) FA34 subclones or (B) FA121 subclones.
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Table 1. IC50 values of different FA34 and FA121 -parental and -resistant subclones against the three
ALK-TKIs tested. (A) The FA34 and FA121 subclones were incubated with crizotinib, ceritinib or
alectinib (1 nM to 100 µM) for 72 h. Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) assays. The (B) crizotinib or (C) ceritinib resistant subclones of
FA34 and FA121 were treated with crizotinib, ceritinib or alectinib (1 nM to 100 µM) for 72 h. Cell
viability was determined by MTT assay. The values in brackets indicate the fold-changes in IC50
compared with the respective subclones before prolonged TKI exposure. For secondary mutations, the
ALK kinase domain was amplified and was sequenced to detect secondary mutations. Presence of ALK
amplifications in these resistant subclones was determined by qRT-PCR. Wild-type (WT).
A. IC50 values of different FA34 and FA121 subclones against the three ALK-TKIs tested
Subclones/IC50
(µM)

Crizotinib

Ceritinib

Alectinib

FA34.P
FA34.3
FA34.4
FA34.5
FA34.8
FA34.11
FA34.12
FA34.13
FA34.14
FA121.P
FA121.1
FA121.3
FA121.4
FA121.5

0.0416
0.4289
0.9166
2.306
0.2966
0.2075
0.42
0.1015
0.3062
0.03
0.3625
0.096
0.7736
0.0874

0.0535
0.2769
0.2484
0.4287
0.0107
0.0212
0.3371
0.0124
0.0204
0.04
0.0058
0.0004
0.7354
0.0029

0.0004
0.3142
0.0868
1.336
0.0059
0.0061
0.0257
0.0004
0.0224
0.01
0.0165
0.0009
0.6937
0.0067

B. IC50 values and the resistant mechanisms of different crizotinib-resistant subclones against the three
ALK-TKIs tested.
Subclones/IC50
(µM)

Crizotinib

Ceritinib

Alectinib

Secondary
mutation

ALK
amplification

FA34.3SCr
FA34.5SCr
FA34.3HCr
FA34.5HCr
FA121.1SCr
FA121.3SCr
FA121.4SCr
FA121.5SCr
FA121.1HCr
FA121.3HCr
FA121.4HCr
FA121.5HCr

19.6000 (471.2)
20.1200 (8.7)
16.8900 (39.4)
22.9800 (10.0)
1.2560 (3.5)
1.0960 (11.4)
1.9450 (2.5)
0.1884 (2.2)
1.6370 (4.5)
12.860 (134.0)
1.7230 (2.2)
2.7550 (31.5)

2.2790
0.5629
2.2560
1.5690
1.2760
0.3091
0.8955
1.9920
0.0293
1.9000
0.0544
0.0555

61.8400
4.9030
57.0300
31.4300
3.0690
2.0700
1.8940
0.3204
2.0180
3.7180
0.0399
0.6398

WT
WT
WT
WT
WT
WT
WT
WT
WT
ALK, C1156S
WT
WT

YES
YES
YES
YES
NO
NO
YES
YES
YES
NO
YES
YES

C. IC50 values and the resistant mechanisms of different ceritinib-resistant subclones against the three
ALK-TKIs tested.
Subclones/IC50
(µM)

Crizotinib

Ceritinib

Alectinib

Secondary
mutation

ALK
amplification

FA34.5SCe
FA345.HCe
FA121.1SCe
FA121.3SCe
FA121.4SCe
FA121.5SCe
FA121.1HCe
FA121.3HCe
FA121.4HCe
FA121.5HCe

17.6900
24.2400
0.7165
0.3272
1.4610
1.9690
1.5330
7.6780
0.8824
2.5500

5.5000 (12.8)
2.1280 (5.0)
0.4356 (75.1)
0.0557 (139.3)
0.9672 (1.3)
1.2190 (1.7)
0.5631 (97.1)
2.5650 (6412.5)
1.1534 (1.6)
0.4636 (159.8)

18.3600
11.2600
0.2278
0.0965
0.1533
0.3851
10.8500
9.0510
0.0845
7.5000

WT
WT
WT
ALK, T1151M
ALK, T1151M
WT
WT
WT
ALK, T1151M
WT

YES
YES
NO
YES
NO
NO
YES
YES
NO
YES
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2.2. Establishment of Drug Resistant Lung Adenocarcinoma Cell Lines and Determination of Relevant Drug
Resistant Mechanisms
All subclones of the two ALK cell lines (FA34 and FA121) were continuously incubated with
crizotinib (Table 1B) or ceritinib (Table 1C) with either stepwise escalation of drug concentrations
or high bolus concentrations. For FA34 subclones (Figure 1F), only FA34.3 and FA34.5 survived
following continuous incubation with crizotinib. The IC50 of FA34.3 against crizotinib increased from
0.4 µM to approximately 20 µM (a 50-fold increase), while the IC50 of FA34.5 increased from 2 µM to
20 µM (a 10-fold increase) in the resistant subclones (named FA34.3SCr, FA34.3HCr, FA34.5SCr and
FA34.5HCr, respectively).
All four subclones of FA121 (Figure 1G) survived after prolonged incubation with crizotinib, and
their IC50 against crizotinib increased from 2-fold to 130-fold. Continuous ceritinib exposure eliminated
most of the FA34 subclones but not those of FA34.3 and FA34.5 (named FA34.3SCe, FA34.3HCe,
FA34.5SCe and FA34HCe, respectively). The IC50 of resistant FA34.5 increased from 0.4 µM to 5 µM
or 2 µM in two treatment methods. All the FA121 subclones survived after prolonged crizotinib or
ceritinib treatment. These results also suggested that different levels of intratumoural heterogeneity
among patients may be associated with different clinical outcomes during ALK-TKI treatment.
Direct sequencing of the cDNA amplicon of the ALK kinase domain revealed a resistant
mutation C1156S in FA121.3HCr; IC50 of the recipient cells against crizotinib increased from
0.1 µM to approximately 13 µM (Table 1B). Another resistant mutation T1151M was found in
several ceritinib-treated cell lines including FA121.3SCe and FA121.4SCe, and also in FA121.4HCe
(Table 1C). ALK gene copy number gain (CNG) representing ALK gene amplifications was found in
all FA34-resistant subclones regardless of treatment with crizotinib or ceritinib. Some FA121-resistant
subclones also acquired ALK-CNG after treatment with crizotinib or ceritinib.
2.3. Identification of ALK-TKI Resistance-Related EV-RNAs in Lung Adenocarcinoma Subclones
Next we compared the intracellular (Figure 2A) and EV-associated (Figure 2B) expression of
miRNAs in the ALK-TKI-sensitive subclones FA34.8 and the drug-resistant subclones FA34.5. This
would allow for identification of EV-miRNAs that were differentially expressed in drug-resistant cells
and in the EVs they released.
Intracellular miR-21-5p and miR-486-3p level was significantly increased in drug-resistant
subclones (excepted miR-21-5p in FA34.5HCe) (Figure 2A). Among these 20 miRNAs, only 8 were
detected in EVs released from FA34 cells. EV-miR-486-3p was upregulated in drug-resistant subclones
(Figure 2B), but EV-miR-21-5p level decreased. It has been previously demonstrated that both tumour
suppressor genes PTEN and MSH2 can be the common regulatory targets of miR-486-3p [13,14] and
miR-21-5p [15,16]. We reconfirmed that ectopic expression of miR-486-3p and miR-21-5p could repress
their mRNA expression (Figure 2C).
2.4. Characterization of Isolated EVs
EVs were isolated from conditioned medium (CM) of FA34 or from serum samples from patients
with lung cancer and prescribed ALK-TKI treatment. The average size of EVs from CM and serum
was 109 nm and 84 nm respectively (Figure 2D). The purity of EVs was verified by the presence of
EV protein marker CD63, and the absence of non-EV protein marker GP96 and GAPDH (Figure 2E).
To confirm EV uptake, FA34.8 was incubated with isolated EVs labelled with DiD for one hour;
exosome uptake in recipient cells was demonstrated by fluorescence microscopy (Figure 2F). The
cells pre-treated with EIPA, a Na+ -H+ exchange inhibitor that blocks micropinocytosis, demonstrated
markedly reduced exosome uptake (Figure 2F, lower left).
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2.5. Transfer of EV-RNAs Induced Drug-Resistance and Cell Migration
To evaluate the functional effects of EV transfer between TKI-sensitive and -resistant subclones,
EVs were isolated from the TKI-resistant subclones FA34.5. These EVs were transferred to TKI-sensitive
Cancers 2018, 10, x
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2.6. Prognostic Value of Circulating EV-RNAs in ALK-Translocated Lung Adenocarcinoma Patients
The expression level of circulating EV-RNAs in two ALK-translocated lung adenocarcinoma
patients at different stages of treatment (Figure 4A,B) were assayed (complete profile in Figure
S2A,B). The expression patterns of EV-RNAs were very similar in both patients. Serum EV-miR-21-5p
showed a steady decrease during the course of treatment, through baseline, stable disease and disease
progression; while EV-miR-486-3p, lncRNA MEG3 and XIST increased throughout the course of
treatment. These results suggest that these serum EV-RNAs may serve as circulating biomarkers to
enable early detection of disease recurrence in patients with ALK-translocated lung adenocarcinoma.

patients at different stages of treatment (Figure 4A and B) were assayed (complete profile in Figure
S2A,B). The expression patterns of EV-RNAs were very similar in both patients. Serum EV-miR-215p showed a steady decrease during the course of treatment, through baseline, stable disease and
disease progression; while EV-miR-486-3p, lncRNA MEG3 and XIST increased throughout the course
of treatment. These results suggest that these serum EV-RNAs may serve as circulating biomarkers
to enable early detection of disease recurrence in patients with ALK-translocated lung
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Figure 4. Expression changes of serum EV-associated miR-21-5p, miR-486-3p, MEG3, and XIST in
ALK-translocated NSCLC patients during crizotinib or ceritinib treatment. The relative expression
levels of EV-associated miR-21-5p (upper left), miR-486-3p (upper right), MEG3 (lower left), and XIST
(lower right) lncRNA in serial serum EV samples from ALK-translocated lung cancer patients treated
with (A) crizotinib and with (B) ceritinib. The level of serum EV-associated miRNAs and lncRNA was
determined by qPCR in the serial serum samples collected before treatment (Baseline), when disease
was under control (Stable disease), and after disease progression (Disease progression). The values
are presented as mean ± S.D. from technical triplicate experiments. * p < 0.05, ** p < 0.01, *** p < 0.001
vs. Baseline.

3. Discussion
The results of this study suggest that transfer of EV-RNAs can sustain tumour subclonal
heterogeneity. Although ALK inhibitors are effective in most patients with EML4-ALK positive
NSCLC, the eventual development of acquired resistance remains a major concern in the treatment of
EML4-ALK translocated lung adenocarcinomas. Lung tumours consist of different subpopulations of
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cancer cells with different phenotypic expression of cancerous properties as well as drug sensitivity [20].
Under selective pressure from chemotherapy or targeted-therapy, the interactions between subclones
of cancer cells may affect treatment response and efficacy. In the lung adenocarcinoma cell line models
established in this study, different FA34 subclones showed variable sensitivity to ALK-TKI, and two
subclones of FA34 were able to develop resistance to ALK-TKIs. The first round of drug treatment
may have introduced a selective pressure and could have suppressed the TKI-sensitive subclones (i.e.,
FA34.4, .8, .11, .12, .13 and .14). The surviving resistant subclones (i.e., FA34.3 and .5) could become the
dominant clone after treatment. Nonetheless the results of in vitro EV transfer experiments suggest
that the TKI-resistant subclones could release EV with low miR-21-5p and high miR-486-3p, and a
high level of lncRNAs MEG3 and XIST. The EV-RNAs then modulated TKI-sensitivity by inhibition of
tumour suppressors PTEN and MSH2 of the recipient subclones and enhanced their survival. This
observation may in part explain the intratumoural heterogeneity of chemo-sensitivity.
In this study, we investigated the biological functions of EV-miRNAs and EV-lncRNAs. The role
of miR-21-5p has been extensively studied in various cancers [21]. The fact that over-expression of
miR-21-5p has been found in most tumours suggests that it may be an oncomiR that contributes to
cancer cell proliferation, inhibition of apoptosis, promotion of angiogenesis [22] and metastasis [23].
The large-scale prospective clinical study BIOMILD (NCT02247453) selected 24 previously identified
plasma miRNAs including miR-21 as diagnostic signatures for lung cancer screening. A recent study
using next-generation sequencing (NGS) has shown that exosomal miR-21-5p is downregulated rather
than upregulated in lung cancer patients compared with healthy controls. These conflicting results
regarding the expression of miR-21-5p between tissue and EVs [11,24] suggests its distinct roles
in lung cancer. In our study, the contradictory expression pattern of miR-21-5p (high intracellular
expression but low in EV) in resistant cells led us to further explore other EV-associated components,
including EV-lncRNAs, that could affect the level of miR-21-5p in EV-recipient cells. The resistant
cells produced only EVs with relatively low expression of miR-21-5p and could not have led to
down-regulation of intracellular miR-21-5p, and subsequently PTEN and MSH2 in the recipient cells.
The regulatory functions of lncRNAs XIST and MEG3 mediated sponging of miR-21-5p adding another
layer of complexity in subclonal communications via EVs, but also highlighted the precise control
EV-cargo sorting.
For miR-486, both -3p and -5p strands have been proposed as oncomiR [25,26]. Intracellular
miR-486-5p has been shown to directly suppress NF-κB-negative regulators and promote cancer
aggressiveness through activation of NF-κB [25]. The prognostic power of exosomal miR-486-5p
in NSCLC has also been demonstrated in a recent study using NGS [11]. Since a single protein
can be regulated by multiple miRNAs, a cellular response such as drug resistance may involve
numerous miRNAs. As cancer cells often secrete several times more EVs than normal cells [27], a panel
of circulating EV-miRNA from NSCLC patients could have the potential for use as non-invasive
circulating biomarkers for lung cancer patients [28].
Data from recent clinical trials show that ceritinib and alectinib, two second-generation ALK
inhibitors, are superior to crizotinib in the first-line setting in terms of progression-free survival,
especially for patients with brain metastases [29,30]. The clinical use of ALK-TKIs could be enhanced
with companion biomarkers. Liquid biopsy, especially with blood sampling, may reveal the changes
in oncogenic mutations along a treatment course. The resistant cell-derived EV-RNAs identified
in this study may provide a source of biomarkers for monitoring of disease and treatment course.
The use of serum EV-RNAs as promising biomarkers has emerged for various cancers because of
their stability in circulation [10]. In contrast to free circulating miRNA, EV-miRNAs are more stable.
miRNA could be packaged and enriched in EVs and then actively secreted in extracellular space
for trans-cellular communication, taking part in oncogenic processes like tumour metastasis [23,31],
angiogenesis [22], and chemoresistance [32]. Since specific RNA sorting [33] and cell-free miRNA
biogenesis machinery [34] has been found in EVs, these mechanisms may indicate that EV-RNAs should
better represent the cellular conditions than the randomly released cell-free circulating RNA [11,24].
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There are some limitations in this study. First, the EV-RNA signatures, low EV-miR-21-5p and high
miR-486-3p, MEG3 and XIST identified in this study require clinical validation in a larger patient cohort
to confirm their prognostic relevance in ALK-translocated lung cancer. Second, the results from this
study are relevant to ALK-translocated lung cancer. Whether the same EV-RNA profiles are evident
in other histological or molecular subtypes of lung cancer warrants further investigation. It is worth
mentioning that the two cell lines used in the present study were established from malignant pleural
effusions of ALK-TKI-naïve patients previously treated with standard platinum-based chemotherapy.
Undoubtedly the EV-cargo was affected by the chemotherapy through multiple mechanisms [35]. The
extent to which this could impact the predictive power of the selected exosomal miRNAs should be
validated in a larger cohort. Further experiments are also warranted to explore the biological effects of
EVs on relevant cancer metabolomics and epigenomic regulation of tumour heterogeneity. The novel
ALK-translocated lung cancer cell lines together with their subclones will enable further understanding
of the development of drug resistance within the heterogeneous tumour microenvironment. This will
shed light on drug resistance mechanisms in ALK-translocated lung cancer.
4. Materials and Methods
4.1. ALK-Translocated Lung Adenocarcinoma Cell Lines
All clinical specimens were collected after informed written consents had been given by the
respective subjects. The study was approved by the University of Hong Kong/Hong Kong Hospital
Authority Hong Kong West Cluster Institutional Review Board/Ethics Committee (UW 11–326).
The EML4-ALK lung adenocarcinoma cell line FA34 was established from a malignant pleural
effusion of a 34 year-old female non-smoker with left lower lobe adenocarcinoma as described in
a previous report [36]. Another EML4-ALK lung adenocarcinoma cell line FA121 was established
from the pleural fluid of a 44-year-old male non-smoker with stage IV EML4-ALK translocated lung
adenocarcinoma. Both patients had received standard platinum-based chemotherapy but had not been
treated with an ALK-inhibitor prior to collection of pleural fluid.
The subclones of FA34 and FA121 were selected with single cell cloning either by serial dilution
or by cloning cylinders. Eight subclones were generated from the FA34 parental cell line (FA34P) (the
subclones were named FA34.3, FA34.4, FA34.5, FA34.8, FA34.11 (established by serial dilution), and
FA34.12, FA34.13, and FA34.14 (established by cloning cylinders). Four subclones were generated from
the FA121 parental cell line (FA121.P) (the subclones were named FA121.1, FA121.3, FA121.4, FA121.5
and they were all established by serial dilution methods). The parental and the subclones of FA34 were
maintained in RPMI 1640 medium with 10% fetal bovine serum (FBS) (Gibco, Grand Island, NY, USA).
The FA121 parental and subclones were maintained in ACL4 medium [37] supplemented with 10%
FBS. All cell lines were cultured at 37 ◦ C in a 5% CO2 incubator. All cell lines were established with
more than 50 passages as an adherent monolayer. The identity and purity of all parental cell lines and
the subclones were authenticated by polymorphic short tandem repeat (STR) DNA profiling assay
(Genetica DNA Laboratories Inc, Burlington, NC, USA).
4.2. Fluorescence In Situ Hybridization (FISH)
Cultured cells were harvested and fixed onto positively-charged glass slides. ALK FISH was
performed with the Vysis ALK Dual Specific Break Apart FISH Probe Kit (Abbott Molecular, Des
Plaines, IL, USA) according to the manufacturer’s protocol. The images were analyzed and captured
by the Isis FISH imaging system (MetaSystems, Altlussheim, Germany).
4.3. Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
To identify the variation of EML4-ALK in these newly established lung adenocarcinoma cell
lines and subclones, RT-PCR was performed with primers specific to EML4 intron 13 and ALK intron
19 [38]. Total RNA was extracted from cultured cells using Trizol (Invitrogen, Carlsbad, CA, USA).
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Complementary DNA (cDNA) was synthesized using the QuantiTect reverse transcription kit (Qiagen,
Hilden, Denmark) according to the manufacturer’s instruction. The types of EML4-ALK fusion mRNA
variants were identified by RT-PCR using the Fusion-RT-S and Fusion-RT-AS primers [38] (Table S1).
PCR was performed with initial denaturation at 95 ◦ C for 4 min, followed by 40 cycles of amplification
(95 ◦ C for 30 s, 55 ◦ C for 30 s, and 72 ◦ C for 2.5 min), and final extension at 72 ◦ C for 10 min. The PCR
products were resolved on 1.5% agarose gel and stained with SYBRsafe.
4.4. Establishment of Lung Adenocarcinoma Cell Lines with Resistance to Crizotinib or Ceritinib
To study the ALK-TKI resistant mechanisms, we established ALK-TKI-resistant cell lines. The
subclones of FA34 and FA121 were incubated with crizotinib (Cr) or ceritinib (Ce) (Selleck Chemicals,
Houston, TX, USA) with stepwise escalation (labelled with the suffix S) of drug concentrations
(crizotinib: 0.02, 0.05, 0.2 µM; ceritinib: 0.01, 0.02, 0.04 µM), or high bolus concentrations (labelled
with the suffix H) (crizotinib: 0.4 µM, ceritinib: 0.1 µM). IC50 values were determined by non-linear
regression curve fitting using GraphPad Prism software 6.01. The IC50 of the drug-resistant cell lines
against different ALK-TKIs was determined after 20 passages. The cells that survived after prolonged
exposure to TKIs were considered drug-resistant cell lines. Drug-resistant cell lines treated with
first-generation ALK-TKI crizotinib were annotated with suffix Cr; resistant cell lines treated with
second-generation ALK-TKI ceritinib were annotated with suffix Ce.
4.5. Cell Viability Assay
FA34 and FA121 cells and their respective subclones were seeded onto 96-well plates overnight.
After drug treatment for 72 h, the cells were incubated with (3-(4,5-dimethylthiazol-2-yl)-,5-dipheny
ltetrazolium bromide (MTT, USB Affymetrix, Santa Clara, CA, USA) (0.5 mg/mL). After incubation
for 3 h, the medium was removed and the purple formazan product was dissolved with DMSO.
Absorbance at wavelength 570 nm and 690 nm was measured using a microplate reader (CLARIOstar,
BMG LABTECH, Mornington, Australia).
4.6. Detection of Secondary ALK Mutations or Amplifications
Secondary mutations in resistant cell lines were detected by direct sequencing of ALK kinase
domain cDNA amplicon. In brief, the primers (EML4-E20-F and EML4-ALK-4193-R) (Table S1) flanking
the ALK kinase domain coding region were used for PCR amplification and the amplicon size was
1055 bp. The resolved PCR product extracted from agarose gel was subjected to direct sequencing
(Tech Dragon Ltd., Hong Kong, China) with the primer 3221-F (Table S1). ALK amplification was
determined by quantitative PCR (qPCR) assay using QuantiFast SYBR Green PCR (Qiagen, Valencia,
CA, USA) with the primers ALK-F and ALK-R (Table S1). The relative copy number ratio of ALK was
expressed in comparison with the reference gene LINE1 [39].
4.7. Extraction and Characterization of EVs Released from Lung Cancer Cells into Conditioned Medium and
Serum
Serum samples from two ALK-translocated lung adenocarcinoma patients were centrifuged
at 1500× g at 4 ◦ C for 10 min to remove any cells. The supernatant was passed through 0.22 µm
filters to remove contaminating cell debris and large EVs. Conditioned medium (CM) was collected
from cells cultured in RPMI-1640 or ACL4 media supplemented with exosome-depleted FBS (System
Biosciences, Mountain View, CA, USA) and also filtered through 0.22 µm filters prior to EV isolation.
EVs in conditioned media or serum samples were isolated using miRCURY Exosome Isolation Kits
(Exiqon, Vedbaek, Denmark) in accordance with the manufacturers’ protocols. The isolated EVs
were characterized by particle size analysis and immunoblot analysis. The particle size distribution
of extracted EVs was examined by NanoSight fluorescent nanoparticle tracking analysis (System
Biosciences). The EV protein markers were confirmed by immunoblot analysis with specific anti-CD63
(1:1000, Proteintech, Rosemont, IL, USA), anti-GP96 (1:1000, Invitrogen), and anti-GAPDH (1:10000,
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Proteintech) antibodies. All relevant data of our experiments were submitted to the EV-TRACK
knowledgebase (EV-TRACK ID: EV180001) [40].
4.8. EV-RNA Extraction, TaqMan microRNA Assay and Quantitative PCR (qPCR)
To elucidate the role of EV-miRNA in intratumoural heterogeneity, the expression level of 20
cancer-related miRNAs in different FA34-sensitive and -resistant subclones was assayed. The selection
of this panel of cancer-related miRNAs was based on their biological relevance to different types
of cancer [41,42]. Total EV-RNA was first extracted by TRIzol LS Reagent (Invitrogen). EV-miRNA
quantitation was performed using TaqMan microRNA Assays (Applied Biosystems, Foster City, CA,
USA). Then DNase-treated EV-RNA was converted to complementary DNA (cDNA) with specific
stem-loop primers. All real-time PCR reactions were carried out in a StepOnePlus real-time PCR
system (Applied Biosystems). For intracellular miRNAs, the relative expressions of the target miRNAs
were normalized to the expressions of small RNA RNU6B. For EV-miRNAs, the relative expressions
of the target miRNAs were normalized to the average threshold cycle (Ct) values of all miRNAs
determined in the same sample. For quantitation of EV-lncRNAs MEG3 and XIST, EV-RNA was
reversely transcribed into cDNA by the QuantiNova Reverse Transcription Kit (Qiagen). The relative
expression levels of the EV-lncRNAs were normalized to the expression levels of GAPDH. The relative
expression levels of cellular PTEN and MSH2 were quantified by the same method as mentioned above.
The sequences of primers used are listed in Supplementary Table S1.
4.9. EV Transfer
The effects of EV transfer from resistant subclones to sensitive subclones were assessed. EVs from
the different resistant subclones were isolated and transferred to TKI sensitive subclones. Isolated EVs
were labelled with 1,10 -dioctadecyl-3,3,30 ,30 ,-tetramethylindodicarbocyanine, 4-chlorobenzenesulfnate
salt (DiD) (5 µg/mL) (Invitrogen). Cells were pre-incubated with 5-(N-ethyl-N-isopropyl)-amiloride
(EIPA, 50 µM, Tocris Bioscience, Bristol, UK) for 30 min as indicated. Uptake of EVs in recipient cells
was confirmed using fluorescence microscopy. To determine transfer of EV cargos, cellular RNA in
recipient cells was extracted and the expression of specific miRNA and lncRNA assayed by qPCR as
described above. To determine the functional effects of EV transfer, cell viability and motility were
determined by MTT cell viability assay and cell migration assay respectively. Cell migration was
performed using the transwell migration assay in EV recipient cells [43]. Briefly, ALK-TKI-sensitive
subclones FA34.8 were treated with EVs (10 µg/mL isolated from CM of drug resistant subclones for
24 h. Treated cells were then subjected to transwell migration assay with corresponding EV loaded
into the lower chamber. After further incubation for 20 h, the migrated cells were fixed and stained;
the stain of the migrated cells was eluted for measurement of absorbance at 550 nm.
4.10. Serial Circulating EV-RNA Levels in ALK-Translocated Lung Adenocarcinoma Patients on ALK-TKI
Treatment
Serial blood samples were taken from two patients with ALK-translocated lung adenocarcinoma
along their treatment course. The first patient (Figure 4A) was a 56 year-old, male, non-smoker with a
left upper lobe lung adenocarcinoma with ALK rearrangement confirmed by FISH on endobronchial
biopsy. He had mediastinal lymphadenopathy and malignant left pleural effusion. Baseline blood was
taken before commencement of crizotinib (Baseline), when the patient had stable disease on crizotinib
(Stable disease), and when the patient had disease progression with enlargement of the left upper
lobe mass while on crizotinib (Disease progression). The second patient (Figure 4B) was a 79 year-old,
male, non-smoker with a left lower lobe lung adenocarcinoma and malignant left pleural effusion.
EML4-ALK translocation was confirmed by endobronchial biopsy and the patient was initially treated
with crizotinib but there was clinical disease progression despite three months of crizotinib. Therapy
was changed to ceritinib with blood taken (Baseline). The patient showed stable disease (Stable disease)
for the next eleven months before the disease progressed again (Disease progression) while on ceritinib.
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All blood samples were processed immediately upon collection and the respective serum portions were
kept frozen at −80 ◦ C for later analysis. Serum EV isolation, characterization and EV-RNA extraction
were performed as described in previous sections. The study was approved by the Institutional Review
Board/Ethics Committee of the Hong Kong University/Hong Kong Hospital Authority Hong Kong
West Cluster (HKU/HA HKWC IRB/EC UW 16-104).
4.11. Statistical Analysis
EV-RNAs and proteins levels are reported as mean ± standard deviation. Normal distribution of
quantitative data was confirmed. Between-group comparisons were performed with either Chi-square
tests or Student’s t-tests where appropriate; multiple group comparisons were performed with one-way
ANOVA followed by Tukey’s multiple comparisons post hoc. All statistical analyses were performed
using GraphPad Prism software 6.01 (GraphPad Software Inc., San Diego, CA, USA). Statistical
significance levels were all two-sided and were taken at p < 0.05.
5. Conclusions
A panel of drug resistant subclones of ALK-translocated lung adenocarcinoma cell lines, namely
FA34 and FA121, was established. The established subclones demonstrated a range of different drug
sensitivity towards different ALK-TKIs. EV transfer from ALK-TKI-resistant subclones to sensitivity
subclones showed potential mediation of drug resistance. Serum EV-miR-21-5p, miR-486-3p, MEG3
and XIST levels may correlate with disease progression and treatment response in patients with
ALK-translocated lung adenocarcinoma prescribed ALK-TKI treatment (Figure 5). This warrants
further confirmation in a larger cohort. This study highlighted the urgent need to develop a deeper
understanding of intratumoural heterogeneity via EV transfer. The results also imply that EV-RNAs
may serve as a novel circulating biomarker for monitoring treatment response and progress of
ALK-translocated lung adenocarcinoma.
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course in patients with ALK-translocated lung adenocarcinoma undergoing ALK-TKI treatment.
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